As shown in previous studies, mucosal application of the antigen prior to referral of mice to the asthma protocol inhibits the development of eosinophilic airway inflammation (Figs 2A and 2B and 4A and 4B), mucus hypersecretion (Fig 4C and 4D), Th2 cytokine production (Fig 3A–3D), Ag-specific cell proliferation (Fig 3E) and IgE levels in serum (Fig 2C) in WT mice. Here, RENBP is linked to asthma.